Johnson & Johnson (NYSE:JNJ) Shares Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on January 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on January 8th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Old Dominion Freight Line (NASDAQ:ODFL) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Palo Alto Networks (NASDAQ:PANW) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Kinder Morgan (NYSE:KMI) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Norfolk Southern (NYSE:NSC) on 1/21/2025.
• Purchased $1,001 – $15,000 in shares of Cardinal Health (NYSE:CAH) on 1/21/2025.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $151.27 on Thursday. The company has a market cap of $364.20 billion, a PE ratio of 22.75, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a fifty day moving average price of $147.76 and a two-hundred day moving average price of $156.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 earnings per share. Research analysts expect that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.28%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds have recently made changes to their positions in the business. Dark Forest Capital Management LP bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $223,000. Bontempo Ohly Capital Mgmt LLC lifted its holdings in shares of Johnson & Johnson by 0.8% during the second quarter. Bontempo Ohly Capital Mgmt LLC now owns 14,650 shares of the company’s stock valued at $2,141,000 after acquiring an additional 115 shares during the period. Magnolia Capital Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $21,803,000. Nemes Rush Group LLC increased its position in shares of Johnson & Johnson by 4.4% during the 2nd quarter. Nemes Rush Group LLC now owns 51,269 shares of the company’s stock worth $7,494,000 after purchasing an additional 2,171 shares in the last quarter. Finally, NewEdge Advisors LLC raised its position in Johnson & Johnson by 11.5% in the 2nd quarter. NewEdge Advisors LLC now owns 268,520 shares of the company’s stock valued at $39,247,000 after purchasing an additional 27,704 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $170.44.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.